Ignite Creation Date:
2025-12-25 @ 2:08 AM
Ignite Modification Date:
2026-01-18 @ 4:51 PM
Study NCT ID:
NCT07263360
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-04
First Post:
2025-11-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-02-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-23
First Submit QC Date:
None
Study First Post Date:
2025-12-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-23
Last Update Post Date:
2025-12-04
Last Update Post Date Type:
ESTIMATED